Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Feiwu Ran

2PUBLICATIONS

10CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Apr 21, 2026

Long-Term Efficacy and Safety of Taletrectinib in Patients With <i>ROS1</i>+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.

|Apr 03, 2025

Taletrectinib in <i>ROS1</i>+ Non-Small Cell Lung Cancer: TRUST.

Maurice Pérol, Wei Li, Nathan A Pennell

Pageof 1

Frequent Collaborators

2 joint publications

Yongchang Zhang

2 joint publications

Caicun Zhou

1 joint publications

Maurice Pérol

1 joint publications

Nathan A Pennell

1 joint publications

Geoffrey Liu

1 joint publications

Yuichiro Ohe

1 joint publications

Misako Nagasaka

1 joint publications

Enriqueta Felip

1 joint publications

Lyudmila Bazhenova

1 joint publications

Wei Li

Frequent Collaborators

2 joint publications

Yongchang Zhang

2 joint publications

Caicun Zhou

1 joint publications

Maurice Pérol

1 joint publications

Nathan A Pennell

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos